Autonomix Medical, Inc. announced on December 30, 2024, that the United States Patent and Trademark Office (USPTO) issued U.S. patent 12,064,256. This patent, titled 'Systems and Methods for Treating Cancer and/or Augmenting Organ Function,' covers technology for interventionally treating cancerous tumors and cancer-related pain.
The newly granted patent strengthens Autonomix's global patent portfolio, which now includes over 80 issued patents and more than 40 pending applications. This intellectual property protection is crucial as the company advances its potentially groundbreaking technology.
Preclinical mouse study results, previously completed, demonstrated a statistically significant reduction of metastases and tumor mass through targeted nerve ablation. While the current human clinical trial focuses on pain reduction, the company intends to explore the potential of its ablation technology to slow human pancreatic cancer growth and metastasis based on these preclinical findings.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.